Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H27N5O2 |
Molecular Weight | 369.4614 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CCC(CC1)n2c(CCCCOc3ccc4c(CCC(=O)N4)c3)nnn2
InChI
InChIKey=RRGUKTPIGVIEKM-UHFFFAOYSA-N
InChI=1S/C20H27N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h10-11,14,16H,1-9,12-13H2,(H,21,26)
DescriptionCurator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11830753
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/11830753
Cilostazol is a PDE3 inhibitor which is used for the treatment of intermittent claudication. The drug positively affects the platelet aggregation and may be used off-label as a measure to prevent coronary thrombosis/restenosis and stroke recurrence.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094125 |
0.57 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | CILOSTAZOL Approved UseCilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance. Launch Date1.10108161E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
701 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31372190 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILOSTAZOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
9.2 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21718207 |
0.5 mg/kg single, oral dose: 0.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CILOSTAZOL serum | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13724 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31372190 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILOSTAZOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
17.5 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21718207 |
0.5 mg/kg single, oral dose: 0.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CILOSTAZOL serum | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13.5 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31372190 |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
CILOSTAZOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
58.7% EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/21718207 |
0.5 mg/kg single, oral dose: 0.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
CILOSTAZOL serum | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
3.5% |
CILOSTAZOL plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. | 2000 Feb 15 |
|
Cyclic AMP inhibited proliferation of human aortic vascular smooth muscle cells, accompanied by induction of p53 and p21. | 2000 Jan |
|
Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with intermittent claudication. | 2001 |
|
New treatment options in intermittent claudication: the US experience. | 2001 Apr |
|
Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. | 2001 Aug |
|
Is cilostazol more effective than pentoxifylline in the treatment of symptoms of intermittent claudication? | 2001 Feb |
|
Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation. | 2001 Jan |
|
Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol. | 2001 Mar 15 |
|
Effect of cilostazol on restenosis after coronary angioplasty and stenting in comparison to conventional coronary artery stenting with ticlopidine. | 2001 May |
|
Pharmacotherapy of intermittent claudication. | 2001 Nov |
|
Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication. | 2001 Nov |
|
Hepatothermic therapy of obesity: rationale and an inventory of resources. | 2001 Sep |
|
Antiplatelet agent cilostazol potentiates adipocyte differentiation of 3T3-L1 cells. | 2001 Sep |
|
Pharmacologic treatment for intermittent claudication. | 2002 |
|
Cilostazol treatment of claudication in diabetic patients. | 2002 |
|
Pharmacokinetic and pharmacodynamic modeling of the antiplatelet and cardiovascular effects of cilostazol in healthy humans. | 2002 Apr |
|
Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. | 2002 Dec |
|
Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. | 2002 Dec 15 |
|
Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. | 2002 Feb |
|
[Etiology, pathogenesis and management of senile inflammatory pulmonary diseases]. | 2002 Jan |
|
Current medical therapies for patients with peripheral arterial disease: a critical review. | 2002 Jan |
|
Cilostazol in intermittent claudication. | 2002 Jan 1 |
|
Successful pharmacologic treatment of lower extremity ulcerations in 5 patients with chronic critical limb ischemia. | 2002 Jan-Feb |
|
Peripheral arterial disease. | 2002 Jun |
|
[Effect of cilostazol on adhesion molecules of STZ-induced diabetic rats]. | 2002 Jun 10 |
|
Treating peripheral arterial disease in patients with diabetes. | 2002 Mar |
|
Evidence-based symptom relief of intermittent claudication: efficacy and safety of cilostazol. | 2002 Mar |
|
The pharmacology of cilostazol. | 2002 Mar |
|
Recent advances in antiplatelet agents. | 2002 Mar |
|
Effects of a single oral dose of cilostazol on epicardial coronary arteries and hemodynamics in humans. | 2002 Mar |
|
Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication. | 2002 Mar |
|
Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles. | 2002 Oct |
|
Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus. | 2002 Oct |
|
New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation. | 2002 Oct |
|
Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. | 2002 Sep |
|
Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis. | 2002 Sep |
|
Debulking and stenting versus debulking only of coronary artery disease in patients treated with cilostazol (final results of ESPRIT). | 2002 Sep 15 |
|
Pharmacotherapy as adjunctive treatment for serious foot wounds in the patient with diabetes: a case study. | 2003 Apr |
|
Effect of cilostazol on the ventricular escape rate and neurohumoral factors in patients with third-degree atrioventricular block. | 2003 Apr |
|
Cilostazol: an "intermittent claudication" remedy for the management of third-degree AV block. | 2003 Apr |
|
A paclitaxel-eluting stent for the prevention of coronary restenosis. | 2003 Apr 17 |
|
Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. | 2003 Feb |
|
Inhibitory action of cilostazol, a phosphodiesterase III inhibitor, on catecholamine secretion from cultured bovine adrenal chromaffin cells. | 2003 Jan |
|
Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. | 2003 Sep |
Sample Use Guides
The recommended dosage of cilostazol tablets is 100 mg b.i.d. taken at least half an hour before or 2 hours after breakfast and dinner.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21420150
In vitro assay of anti-platelet effects of cilostazol against collagen-induced aggregation using Multiplate produced a graded dose-dependent inhibition curve with IC50 value of 75.4 ± 2.4 uM while it showed a highly sensitive and all-or-none type inhibition response from 25 uM in PFA-100.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C744
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
||
|
NCI_THESAURUS |
C1327
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
||
|
WHO-ATC |
B01AC23
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
||
|
LIVERTOX |
208
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
||
|
WHO-VATC |
QB01AC23
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
||
|
NDF-RT |
N0000175598
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
||
|
NDF-RT |
N0000175086
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C045645
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
73963-72-1
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
C1051
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
N7Z035406B
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
7148
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
M3550
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | Merck Index | ||
|
1134153
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | USP-RS | ||
|
2754
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
DB01166
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
CILOSTAZOL
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
644
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
Cilostazol
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
8312
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
SUB06273MIG
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
21107
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | RxNorm | ||
|
73963-72-1
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
5680
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY | |||
|
CHEMBL799
Created by
admin on Fri Jun 25 21:04:32 UTC 2021 , Edited by admin on Fri Jun 25 21:04:32 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE (PARENT)
METABOLITE ACTIVE (PARENT)
METABOLITE LESS ACTIVE (PARENT)